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Summary
Objective: This work targets the development of a new tool to help develop new anticytokine drugs that prevent or reduce the progression
of arthritic diseases. The specific aim of our study was to establish a fast and reliable in vitro screening assay of cytokine synthesis inhibitors
(TNF, IL-1) which shows better correlation with enzyme assays than previously reported in vitro assays. The test system should be able
to detect p38-MAP kinase inhibitors.
Material and methods: Human peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient centrifugation from
human EDTA-potassium whole blood. Cells were adjusted at 1×106 cells/ml. PBMCs were stimulated with lipopolysaccharide (LPS; E. coli
serotype 026:B6: 1 g/ml) in the presence of test compound (10−5–10−8 M) for 4 h at 37°C in a 5% CO2-incubator. Induced TNF and IL-1
protein were measured by ELISA.
Results: The following are representative examples of inhibitors which effect cytokine synthesis. Corticoid Dexamethasone inhibits IL-1 and
TNF synthesis at IC50 of 38 nM and 25 nM, respectively. ERK1/ERK2 inhibitor U0126 effects cytokine synthesis at IC50 of 0.34 M for IL-1
production and 0.26 M for TNF synthesis.
p38-MAP kinase inhibitor SB 203580 inhibits IL-1- and TNF--synthesis (IC50sof 0.052 M and 0.46 M) in the same degree as p38-MAP
kinase activity (IC50: 0.34 M). Same results could be shown for SB 210313, which had same efficacy on IL-1 and TNF biosynthesis(IC50’s: 1.88 M and 1.01 M) and on p38-MAP kinase (IC50: 6.85 M). Also for SB 202190 this correlation in inhibition of IL-1 and TNF
synthesis (IC50’s: 0.055 M and 1.01 M) and p38-MAP kinase inhibition (IC50: 0.088 M) could be shown.
Conclusion: This study shows the screening assay using PBMCs stimulated with LPS for IL-1 and TNF synthesis is a reliable test system
for the quantification of the effectiveness of new drugs modulating IL-1 and TNF synthesis which is mainly mediated by p38-MAP Kinase.
These assay allows fast detection of IL-1 and TNF synthesis inhibitors with different modes of action, including p38-MAP kinase inhibitors.
The results obtained with our in-vitro screening assay show good correlation with results from enzyme assays. © 2002 OsteoArthritis
Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Proinflammatory cytokines such as IL-1 and TNF play a
central role in the pathogenesis of chronic inflammatory
diseases like osteoarthritis (OA) and rheumatoid arthritis
(RA). Both cytokines are produced in macrophages and
monocytes in response to stimuli like endotoxine, UV-light,
stress or other cytokines. p38-MAP kinase is a pivotal
enzyme in the biosynthesis of IL-1 and TNF. p38-MAP961kinase regulates cytokine production both at the transcrip-
tion1 and the translation level2, and stabilizes cytokine
specific mRNA3,4.
The degradation of arthritic cartilage and other joints is
related to a complex interaction of mechanical and bio-
chemical factors5–7. Among the latter, a number of cata-
bolic factors, including proinflammatory cytokines and
proteases have been demonstrated to play major roles5,8.
Among the different signaling systems activated by pro-
inflammatory cytokines, MAP kinase pathways are believed
to be the key ones9–14. The most predominant ones are
p38, MEK1/2 and Jun kinases, which have been demon-
strated in a number of studies to be involved as key factors
in the synthesis of catabolic factors responsible for inducing
the structural changes seen in arthritic diseases9. p38-MAP
kinase has also been shown to be involved in the synthesis
of proinflammatory cytokines.
A recent study has demonstrated that treatment with
specific a p38-MAP kinase inhibitor in an inflammatory rat
model of arthritis was found to reduce the progression of
structural damage at the same time as it reduced the
synthesis of proinflammatory cytokines15.
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MATERIALS
All the following drugs and solutions were of analytical
grade: Macrophagen-SFM-Medium® (Life Technologies,
Eggenstein, Germany); Histopaque® 1.077-solution, LPS
(E. coli serotype 026:B6), trypan blue solution 0.4%,
gentamicin sulfate (Sigma-Aldrich Chemie, Steinheim,
Germany); salts for Dulbecco’s phosphate buffered saline
(DPBS), DMSO (Merck, Darmstadt, Germany); Cremophor
EL® (Fluka, Buchs, Switzerland); Ethanol (Merck,
Darmstadt, Germany); adenosine-5′-triphosphate disodium
salt hydrate, 4-nitrophenyl phosphate disodium salt,
-glycerolphosphate disodium salt pentahydrate (Fluka,
Buchs, Switzerland); dithiothreitol, sodium orthovanadate,
bovine serum albumin (BSA) (Sigma-Aldrich Chemie,
Steinheim, Germany); MgCl2×6 H2O, NaHCO3, HCl(Merck, Darmstadt, Germany); polyclonal rabbit antibody
detecting ATF-2 phosphorylated on Thr71, polyclonal rabbit
antibody detecting p38-MAP kinase phosphorylated on
Thr180/Tyr182, alkaline phosphatase-linked antirabbit IgG
antibody (New England Biolabs, Beverly, MA, U.S.A.);
alkaline phosphatase-linked goat antirabbit IgG (Santa
Cruz Biotechnology, Santa Cruz, CA, U.S.A.); polystyrene
96-well microtiter plates (Immunolon 4, Dynex
Technologies, Frankfurt a.M., Germany).SUBJECTS
Human whole blood from four healthy donors (male
or female, 20 ml each) was removed by venopuncture
and collected in EDTA-potassium-monovettes (Sarstedt,
Nu¨mbrecht, Germany).ISOLATION OF PBMCS FROM HUMAN WHOLE BLOOD
Human whole blood was diluted 1:3 with 0.9% NaCl-
solution. 8 ml diluted blood was layered on top of 3 ml
Histopaque® 1.077-solution, placed in 15 ml conical tubes
(Falcon 2096, Oxnard, California). After centrifugation at
400×g for 25 min at room temperature, mononuclear cells
were taken off and washed three times in DPBS (136.7 mM
sodium chloride, 8.1 mM sodium phosphate dibasic,
1.5 mM potassium phosphate monobasic, 2.7 mM potass-
ium chloride, 5.5 mM D(+)-Glucose anhydrous). PBMCs
were resuspended at 1×106 cells/ml in Macrophagen-SFM
medium®. Cell viability was determined by trypan blue
exclusion.LPS INDUCTION
390 l cell suspension aliquots were preincubated with
10 l gentamicin sulfate (50 g/ml) 15 min at 37°C in a 5%
CO2-incubator before cells were incubated with LPS(100 l, E. coli serotype 026:B6: 1 g/ml) or Macrophagen-
SFM medium® at 37°C for 4 h in a 5% CO2-incubator.
TNF and IL-1 formation was stopped by placing
samples on ice and addition of ice-cold DPBS. After cen-
trifugation for 12 min at 16 400×g at 2°C supernatants
were removed and stored at −20°C.
TNF and IL-1 were quantified by ELISA (Beckman
Coulter, Krefeld, Germany).QUANTIFICATION OF IL-1 AND TNF mRNA LEVELS
PBMCs (5×106 cells/ml) were stimulated with LPS
(IL-1: 5 g/ml; TNF: 10 g/ml) from 0 h to 4 h at 37°C in
a 5% CO2-incubator. RNA from PBMCs was isolated by
Rneasy® (Qiagen, Hilden, Germany) according to the
manufacturers protocol. mRNA levels were determined
using Quantikine® mRNA (R&D Systems, Minneapolis,
MN, U.S.A.) for quantification of IL-1- and TNF-mRNA.CHARACTERIZATION OF p38-MAP KINASE ACTIVITY
PBMCs (1×107 cells/ml) were treated with LPS (100 g/
ml) from 0 min to 35 min at 37°C in a 5% CO2-incubator.
Cell lysates were used for the kinase reaction. 50 l cell
lysate and 50 l of ATP-mixture (50 mM HCl, 10 mM MgCl2,
10 mM -glycerolphosphate, 100 g/ml BSA, 1 mM DTT,
1 mM ATP, 0.1 mM Na3VO4) were added in a ATF-2 coated
microtiter plate and incubated at 37°C for 1 h. After being
washed three times, the plate was incubated with
phosphoATF-2 antibody (1:2000) for 1 h at 37°C. After
three washes, alkaline phosphatase labeled goat antirabbit
IgG (1:2000) was added for 1 h at 37°C. After a next
washing step alkaline phosphatase substrate solution
(3 mM 4-NPP, 50 mM NaHCO3, 50 mM MgCl2) was added
for 1.5 h at 37°C. The formation of 4-nitrophenolate was
measured at 405 nm using a microtiter plate reader.WESTERN BLOT ANALYSIS18
PBMCs (1×107 cells/ml) were treated with LPS (100 g/
ml) from 0 min to 35 min at 37°C in a 5% CO2-incubator.
To cell lysates, 5×concentrated SDS-electrophoresis
sample buffer (final concentrations: 0.4% SDS, 2.9%
2-mercaptoethanol, 5% glycerol and 0.1% BPB in 12 mMAfter the introduction of anticytokine therapy for treat-
ment in chronic inflammatory diseases, such as arthritis,
p38-MAP kinase became a valid target for many drug
discovery programs.
In the past, several test models designed to study
p38-MAP kinase inhibitors have been reported. For
example, Hartman et al.16 investigated the effects of drugs
on IL-1 and TNF synthesis in human whole blood.
Wadsworth et al.17 studied p38-MAP kinase inhibitors in
PBMCs as well as in an isolated p38-MAP kinase enzyme
assay.
These test systems are useful tools for the investigation
of novel p38-MAP kinase inhibitors but have two disadvan-
tages: (1) most isolated p38-MAP kinase enzyme assays
work with [32-P]ATP; (2) the screening assays based on
human whole blood or PBMCs are time consuming and
IC50-values show only low correlation with IC50-values
obtained from enzyme assays.
To allow best possible correlation with human whole
blood assays and to the situation in man freshly isolated
human PBMCs should be used rather than cell lines. As
interindividual variability is a general problem cells from at
least four donors should be used.
The aim of our study was to develop a test system using
freshly isolated, pooled human mononuclear cells with
the advantages of short incubation times, no radioactivity,
reproducible results and good correlation with IC50-values
obtained with the isolated p38-MAP kinase enzyme
assay.
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95°C for 5 min. Proteins were electrophoresed on 10%
SDS-polyacrylamide gels and then transferred to PVDF
membranes. The membranes were probed with dual-
phosphospecific (Thr180/Tyr182) rabbit anti-p38-MAP
kinase antibody and goat alkaline phosphatase-linked anti-
rabbit IgG antibody (1:1000) (New England Biolabs Inc.,
Beverly, MA, U.S.A.).DETERMINATION OF INHIBITORY POTENCY OF TEST CANDIDATES
OF p38-MAP KINASE
The activity was measured using method of Forrer
et al.19. Microtiter plates were coated with 50 l ATF-2-
solution (10 g/ml) 1 h at 37°C. Plates were washed three
times and 50 l kinase mixture (50 mM Tris–HCl, 10 mM
MgCl2, 10 mM -glycerol phosphate, 100 g/ml BSA, 1 mM
DTT, 100 M ATP, 100 M Na3VO4, 10 ng p38 activated)
with or without inhibitor was added to the wells and incu-
bated for 1 h at 37°C. After three washes, plates were
incubated with phospho-ATF-2 antibody (1:2000) for 1 h at
37°C. After washing plates three times, alkaline phos-
phatase labeled goat antirabbit IgG (1:2000) was added for
1 h at 37°C (to capture the antibody phosphorylated-
protein-substrate complex). After three washes, alkaline
phosphatase substrate solution (3 mM 4-NPP, 50 mM
NaHCO3, 50 mM MgCl2, 100 l/well) was added for 1.5 h at
37°C. The formation of 4-nitrophenolate was measured at
405 nm using a microtiter plate reader (Molecular Devices,
Ismaning, Germany). IC50-values were calculated.STANDARD TEST CONDITIONS TO EVALUATE CYTOKINE SYNTHESIS
INHIBITORS
PBMCs were prepared from human whole blood
(potassium-EDTA) used within 4 h after being drawn from
healthy donors as described above. After washing cells
three times in DPBS, PBMCs were suspended at a con-
centration of 1×106 cells/ml in Macrophagen-SFM medium.
390 l cell suspension was preincubated with 5 l
gentamicin sulfate (50 g/ml) and 5 l test compound
(10−5–10−8 M, 1% DMSO) for 15 min at 37°C in a 5%
CO2-incubator. PBMCs were stimulated with 100 l LPS(E. coli serotype 026:B6, 1 g/ml) for 4 h at 37°C in a 5%CO2-incubator for cytokine production. The reaction was
terminated by placing samples in a ice bath and centrifug-
ing for 12 min at 16 400×g at 2°C.
Supernatants were used to quantify TNF and IL-1 by
ELISA (Beckman Coulter, Krefeld, Germany).
Potency of the test compounds (IC50-values) was calcu-
lated by blotting percentage inhibition of IL-1 and TNF
synthesis vs concentration on a semi-logarithmic scale.
Potency of test compounds can also be determined in
human whole blood. Human whole blood (potassium-
EDTA) was used within 4 h after being drawn from healthy
donors. 400 l whole blood was preincubated with
50 l test compounds (10−4–10−7 M, 1% Cremophor
EL®/Ethanol (66.6%/33.3%), 50 g/ml gentamicin sulfate)
15 min at 37°C in a 5% CO2-incubator. Blood was stimu-
lated for 4 h with 50 l LPS (E. coli serotype 026:B6;
1 g/ml) at 37°C in a 5% CO2-incubator. The reaction was
terminated by placing samples on ice and centrifuging for
15 min at 1000×g at 4°C. Plasma samples were used for
quantification of IL-1 and TNF by ELISA.ResultsLPS-INDUCES IL-1 AND TNF SYNTHESIS
The time course of IL-1 and TNF synthesis from
PBMCs after treating with LPS (1 g/ml) for 24 h are shown
in Fig. 1.
IL-1 and TNF were measurable 3 h and 1 h after LPS
treatment respectively. IL-1 reached a maximum concen-
tration after 6 h of incubation and TNF a maximum con-
centration after 12 h. There was no additional change in
IL-1 and TNF levels up to 24 h. In unstimulated PBMCs,
cytokine synthesis was very low, indication that there is no
substantial stimulation by pooling cells from different
donors at least during 24 h.Fig. 1. Time course of IL-1 and TNF production by PBMCs. PBMCs were isolated from human whole blood. Cell suspension was adjusted
to 1×106 cells/ml and incubated with LPS (1 g/ml) or DPBS at 37°C for 0 h to 24 h in a 5% CO2-incubator. The reactions were terminated
by placing samples on ice and centrifuging (16 400×g/2°C). IL-1 and TNF were assayed in supernatants by ELISA. Data shown are
representative of at least three independent experiments.QUANTIFICATION OF IL-1 AND TNF mRNA
To demonstrate the expression of IL-1 and TNF during
LPS treatment over a period of 4 h, the formation of
IL-1 and TNF mRNA was quantified by Quantikine® for
IL-1 and TNF mRNA. PBMCs were incubated with
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TNF: 10 g/ml) from 0 h to 4 h.
The mRNA quantification indicated that there were only
very low levels of mRNA for both cytokines in unstimulated
samples. LPS-treated cells showed an IL-1 and TNF
mRNA increase after 0.5 h, with a peak at 2–3 h post
LPS-challenge. mRNA levels decreased after 3 h LPS
treatment. Fig. 2CHARACTERIZATION OF p38-MAP KINASE ACTIVITY
To demonstrate that the signal transduction pathway via
p38-MAP kinase leads to the expression of IL-1 and TNF
in PBMCs after LPS treatment, we examined the phosphor-
ylation of ATF-2 through cell lysate and the formation of
dual phosphorylated p38-MAP kinase by Western blot. The
measurement of ATF-2 phosphorylation through cell lysate
from LPS-treated PBMCs was perfomed because ATF-2 is
a major substrate of p38-MAP kinase in cells and ATF-2
phosphorylation is a good indicator of p38-MAP kinase
activity.
For both assays, PBMCs (1×107 cells/ml) were incu-
bated with Macrophagen-SFM-Medium® (control sample)
or LPS (100 g/ml) from 0 min to 35 min. The analyses of
ATF-2 phosphorylation (Fig. 3) showed that after treating
cells with LPS the amount of ATF-2 phosphorylated by celllysate increases about 85% within 25 min. After 25 min the
phosphorylation activity decreases.
The next step was to establish that the increase in
phosphorylation activity was associated with an increase of
phosphorylated p38-MAP kinase. Western blot analyses
were conducted with a di-phospho-p38-MAP kinase
(Thr180/Tyr182) polyclonal antibody. Only very low levels
of phosphorylated p38-MAP kinase were detected (Fig. 4,
lane 1) in unstimulated samples. The stimulation of PBMCs
with LPS led to an increase of phosphorylated p38-MAP
kinase (lanes 2 and 3).
These facts show that IL-1 and TNF synthesis from
LPS treated PBMCs in our in vitro test system is based on
a de-novo synthesis of both cytokines. This was demon-
strated by an increase in cytokine specific mRNA after LPS
stimulation of PBMCs. The increase in IL-1 and TNF
mRNA results from the upregulation of the p38-MAP kinase
signal transduction pathway that occurs when PBMCs are
stimulated by LPS.Fig. 2. Time course of IL-1(A) and TNF (B) mRNA production by PBMCs. PBMCs were isolated from human whole blood. Cell suspension
was adjusted to 5×106 cells/ml and incubated with LPS (IL-1: 5 g/ml; TNF: 10 g/ml) at 37°C for 0 h to 4 h in a 5% CO2-incubator. The
reactions were terminated by placing samples on ice. RNA was isolated with Rneasy® and mRNA was quantified by Quantikine® for IL-1
or TNF mRNA. Results represent the means and standard errors of four independent experiments.EFFECTS OF IL-1 AND TNF SYNTHESIS INHIBITORS
Four different p38-MAP kinase inhibitors, the Corticoid
Dexamethasone and ERK1/ERK2 inhibitor U0126 were
tested on isolated human mononuclear cells (pooled from
four donors, male and female).
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from 10−5–10−8 M were added to the cell suspension.
Samples were incubated for 4 h at 37°C in a 5% CO2-
incubator with LPS (1 g/ml). p38-MAP kinase inhibitor
activities for SB 203580, SB 210313, SB 202190 and SK&F
86002 were determined according to Forrer et al.19.
Results are shown in Table I.Fig. 3. Time course of p38-MAP kinase activation by LPS. PBMCs were isolated from human whole blood, cell suspension was adjusted to
1×107 cells/ml and incubated with LPS (100 g/ml) at 37°C for 0 min to 35 min in a 5% CO2-incubator. The reactions were terminated by
placing samples on ice. Kinase assays were performed with cell lysates using ATF-2 as substrate. Results represent the means of three
independent experiments.Fig. 4. Western blot analysis of activated p38-MAP kinase in
PBMCs treated with LPS (100 g/ml) at 37°C for 0 to 35 min in a
5% CO2-incubator. Activated p38-MAP kinase was established
with polyclonal antibody detecting p38-MAP kinase phosphor-
ylated on Thr180/Tyr182. Data shown are representative of at least
two independent experiments.Discussion
Proinflammatory cytokines like IL-1 and TNF are
major catabolic factors on cartilage metabolism. Compara-
bly view small molecule drug candidates targets the inhibi-
tion of these cytokines. Here we describe a cell based
screening assay which is fast and easy to handle to
determine IC50-values of proinflammatory cytokine syn-
thesis inhibitors. Such assays are a major prerequisite for
efficient drug discovery programs.
The model allows the broad detection of inhibitors with
very different modes of action, e.g. corticoids, ERK1/2
inhibitors and especially but not only p38-MAP kinase
inhibitors. For a first drug screening this is a valuable asset.
However positive hits have to be followed up by more
specific secondary tests, e.g. isolated enzyme assays.
Examples for inhibition data are: Dexamethasone, a
Corticoid, inhibits IL-1 and TNF synthesis at nanomolar
range (IC50’s: 38 nM and 26 nM). The ERK1/ERK2 inhibitor
U0126 effect inhibition of IL-1 and TNF synthesis at
micromolar concentrations, IC50sare for IL-1 inhibition
0.34 M and for TNF inhibition 0.62 M. p38 MAP kinase
inhibitors like SB 203580, SB 210313, SB 202190 or SK&F
86002 reduce IL-1 and TNF synthesis at micromolar
concentrations, too. For example SB203580 inhibits IL-1synthesis with IC50-value of 0.052 M and TNF production
with IC50-value of 0.46 M.
These data agree with several previously reported IC50-
values for these cytokine synthesis inhibitors20–22.
Monocytes and macrophages are major sources for
proinflammatory cytokines. Their role as cytokine produc-
ing cells is well established in the pathophysiology of
inflammation. They stimulate important inflammatory cells
like synoviocytes, endothelial cells and condrocytes. Our
test systems target these most important cell types which
are not the predominant target for known antiinflammatory
drugs.
Possible advantages over whole blood assays are less
variability due to pooled cells from at least four donors.
Pooling did not prestimulate the cells in the short incubation
time of 4 h. A certain disadvantage is the lack of cross-talk
between different cell types, which is well reflected in whole
blood assays.
Compared with cell lines, freshly isolated PBMCs have
the clear advantage of being much closer to physiologic
conditions, which is also an advantage over assays using
isolated enzymes. Other pros compared with known
enzyme tests are absence of radiolabeled reagents
and coverage of cell penetration properties of the test
candidates.
One weakness of several published cell-based test
systems is the poor correlation with enzyme assays for
p38-MAP kinase inhibition. Therefore we tried to monitor
the whole process of cytokine synthesis after LPS stimula-
tion, e.g. p38-MAP kinase activation, ATF-2 phosphoryl-
ation and mRNA increase and finally IL-1 and TNF
synthesis.
We showed that IL-1 and TNF mRNA synthesis is
induced and p38-MAP kinase signal transduction pathway
is activated after treating cells with LPS. By comparing our
in vitro screening assay with isolated enzyme assay we
found IC50-values obtained with our cell-based screening
assay correlated well with IC50-values calculated with iso-
lated enzyme assay. For SB 203580, SB 210313, SK&F
86002 and other known p38-MAP-Kinase inhibitors
obtained IC50-values for IL-1 and TNF synthesis were
closed to IC50-values measured with isolated enzyme
assay. For example IC50 of p38-MAP kinase inhibition for
SB 203580 is 0.34 M, while IL-1 and TNF biosynthesis
is inhibited with IC50sat 0.052 M and 0.46 M. Also SB
210313 inhibits IL-1 and TNF biosynthesis (IC sof50
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kinase activity is inhibited (IC50 of 6.85 M).
LPS concentrations used in most studies varies between
1 ng/ml and 100 g/ml depending on type and number of
cells and serotype of LPS used. Following kinetic pre-
experiments (data not shown) 1 g/ml proofed to be opti-
mal in terms of cytokine concentrations obtained. Only for
ATF-2 phosphorylation and p38-MAP kinase activation
experiments 100 g/ml was used but with 1×107 cells/ml
instead of 1×106 cells/ml. This experimental setting was
necessary as we worked with cell lysates and not with
immunoprecipitated p38-MAP kinase protein23. This rela-
tively high concentrations is tolerated with no signs of
cytotoxicity (data not shown).
In conclusion, our PBMC based screening assay met our
objectives to develop a fast and reliable method to screen
cytokine synthesis inhibitors including p38-MAP kinase
inhibitors.Table I
Inhibition of IL-1 and TNF synthesis in PBMCs of cytokine synthesis inhibitors and inhibition of p38-MAP kinase
by p38-MAP kinase inhibitors
Inhibitor IC50-values [M]±S.E.M.
IL-1 TNF p38-MAP kinase
SB 203580 N=22 0.052±0.009 N=22 0.46±0.11 0.34
SB 202190 N=2 0.055±0.007 N=2 1.01±0.17 0.088
SB 210313 N=2 1.88±0.37 N=2 4.08±1.2 6.85
SK&F 86002 N=2 0.52±0.028 N=2 5.5±0.35 1
Dexamethasone N=4 0.038±0.0047 N=4 0.026±0.0038 —
U0126 N=2 0.34±0.06 N=2 0.62±0.05 —
Mean IL-1 and TNF synthesis in LPS stimulated PBMCs: IL-1: 189.1±34.6 pg/ml (N=22), TNF:
654.9±100.4 pg/ml (N=22); mean IL-1 and TNF synthesis in unstimulated PBMCs: IL-1: 5.6±5.6 pg/ml
(N=22), TNF: 18.7±12.5 pg/ml (N=22).References
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